Late-onset cytoplasmic body myopathy resembling myotonic dystrophy.

Late-onset cytoplasmic body myopathy resembling myotonic dystrophy.

Bibliographic Details
Main Authors:	Morris, H, Landon, D, Morgan-Hughes, J, Brown, P
Format:	Journal article
Language:	English
Published:	1999

Similar Items

Molecular genetics of myotonic dystrophy.
by: Barnes, P, et al.
Published: (1993)

The myotonic dystrophies: diagnosis and management.
by: Turner, C, et al.
Published: (2010)

Childhood-onset form of myotonic dystrophy type 1 and autism spectrum disorder: Is there comorbidity?
by: Angeard, N, et al.
Published: (2017)

Alternative isoform regulation in myotonic dystrophy
by: Wang, Eric T. (Eric Tzy-shi)
Published: (2012)

Myotonic dystrophy: diagnosis, management and new therapies.
by: Turner, C, et al.
Published: (2014)

Peptide-conjugated PMOs for the treatment of myotonic dystrophy
by: Stoodley, J, et al.
Published: (2022)

New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC).
by: Ashizawa, T, et al.
Published: (2000)

Clinical and molecular aspects of the myotonic dystrophies: a review.
by: Machuca-Tzili, L, et al.
Published: (2005)

Myotonic dystrophy--forgotten aspects of an often neglected condition.
by: Hilton-Jones, D
Published: (1997)

Myotonic dystrophy: practical issues relating to assessment of strength.
by: Whittaker, R, et al.
Published: (2006)

PPMO's as therapeutic modulators for myotonic dystrophy type 1
by: Holland, A, et al.
Published: (2018)

Hearing impairment in patients with myotonic dystrophy type 2
by: van Vliet, J, et al.
Published: (2018)

Three cases of androgen-dependent disease associated with myotonic dystrophy.
by: Cooper, S, et al.
Published: (2003)

Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy.
by: Talbot, K, et al.
Published: (2003)

Positive effect of modafinil on daytime somnolence on patients with Myotonic Dystrophy
by: Talbot, K, et al.
Published: (2002)

Application of antisense conjugates for the treatment of myotonic dystrophy type 1
by: Stoodley, J, et al.
Published: (2023)

Proteomic analysis of the function of DMPK, the myotonic dystrophy protein kinase
by: Luciano, Brenda Sierra, 1965-
Published: (2005)

Preclinical development of antisense conjugates for the treatment of myotonic dystrophy 1
by: Stoodley, J
Published: (2024)

CDHR1-related late-onset macular dystrophy: further insights
by: Yusuf, IH, et al.
Published: (2020)

Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1--the patients' perspective.
by: Hilton-Jones, D, et al.
Published: (2012)

Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1 - The patients' perspective
by: Hilton-Jones, D, et al.
Published: (2012)

A randomised controlled trial of modafinil for treatment of daytime somnolence in myotonic dystrophy
by: Talbot, K, et al.
Published: (2003)

Choroidal new vessels in type 1 myotonic dystrophy-related macular dystrophy respond to anti-VEGF therapy.
by: Zinkernagel, MS, et al.
Published: (2012)

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
by: Cerro-Herreros, E, et al.
Published: (2021)

Using digital technologies to engage with medical research: views of myotonic dystrophy patients in Japan
by: Coathup, V, et al.
Published: (2016)

Proteomic evaluation of Pip6a-PMO treatment for myotonic dystrophy type 1
by: Holland, A, et al.
Published: (2018)

Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy
by: Wagner, Stacey D., et al.
Published: (2017)

Incorrect diagnosis of myotonic dystrophy and its potential consequences revealed by subsequent direct genetic analysis.
by: Barnes, P, et al.
Published: (1994)

Late onset startle induced tics.
by: Tijssen, M, et al.
Published: (1999)

DMPK and myotonic dystrophy : effects of CTG trinucleotide expansion upon DMPK and their contribution to DM pathogenesis
by: Davis, Brigid Michele, 1967-
Published: (2009)

Application of CRISPR-Cas9-mediated genome editing for the treatment of myotonic dystrophy type 1
by: Marsh, S, et al.
Published: (2020)

Myopathies
by: Hilton-Jones, D
Published: (2001)

Myopathies
by: Hilton-Jones, D
Published: (1995)

Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice
by: Klein, AF, et al.
Published: (2019)

MRC Centre for Neuromuscular Diseases 1st (1st December 2010), and 2nd (2nd May 2012) myotonic dystrophy workshops, London, UK and the myotonic dystrophy standards of care and national registry meeting, Newcastle, UK July 2011
by: Turner, C, et al.
Published: (2013)

MRC Centre for Neuromuscular Diseases 1st (1st December 2010), and 2nd (2nd May 2012) myotonic dystrophy workshops, London, UK and the myotonic dystrophy standards of care and national registry meeting, Newcastle, UK July 2011.
by: Turner, C, et al.
Published: (2013)

Does cytosine-thymine-guanine (CTG) expansion size predict cardiac events and electrocardiographic progression in myotonic dystrophy?
by: Clarke, N, et al.
Published: (2001)

Downregulation of the Glial GLT1 glutamate transporter and purkinje cell dysfunction in a mouse model of myotonic dystrophy
by: Sicot, G, et al.
Published: (2017)

Enhanced serum immunoglobulin G clearance in myotonic dystrophy-associated hypogammaglobulinemia: a case series and review of the literature
by: Sasson, SC, et al.
Published: (2019)

Miscellaneous myopathies.
by: Hilton-Jones, D
Published: (2007)